A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes.
OBJECTIVE
This study aimed to develop a new stable nanoformulation of silymarin (SM) with optimum enhanced oral bioavailability and to evaluate its effect as well as mechanism of action as a superior antidiabetic agent over native SM using streptozotocin-induced diabetic rats.


METHODS
SM-loaded pluronic nanomicelles (SMnp) were prepared and fully characterized. Biochemical parameters were performed as well as histological, confocal and reverse-transcription polymerase chain reaction studies on pancreatic target tissues.


CONCLUSIONS
SMnp were found to improve significantly the antihyperglycemic, antioxidant and antihyperlipidemic properties as compared with native SM. In addition, SMnp was found to be a more efficient agent over SM in the management of diabetes and its associated complications due to its superior bioavailability in vivo, and the controlled release profile of SM. [Formula: see text].
Department of Clinical Biochemistry, Faculty of Pharmacy, Mansoura University, 35516, Egypt.
Yousra M
YM
El-Far
Urology & Nephrology Center, Mansoura, 35516, Egypt.
Mahmoud M
MM
Zakaria
Urology & Nephrology Center, Mansoura, 35516, Egypt.
Mahmoud M
MM
Gabr
Department of Clinical Biochemistry, Faculty of Pharmacy, Mansoura University, 35516, Egypt.
Amal M
AM
El Gayar
Center for Materials Science, University of Science & Technology, Zewail City of Science & Technology, 6th October City, 12588 Giza, Egypt.
Ibrahim M
IM
El-Sherbiny
Department of Clinical Biochemistry, Faculty of Pharmacy, Mansoura University, 35516, Egypt.
Laila A
LA
Eissa
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D001786:Blood Glucose / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology; D008099:Liver / Q000378:metabolism; D008297:Male; D008823:Micelles; D053758:Nanoparticles / Q000737:chemistry*; D018384:Oxidative Stress; D010179:Pancreas / Q000378:metabolism; D010316:Particle Size; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D010936:Plant Extracts / Q000737:chemistry*; D011060:Poloxalene / Q000737:chemistry*; D017207:Rats, Sprague-Dawley; D012838:Silymarin / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D014018:Tissue Distribution
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D008823:Micelles; D010446:Peptide Fragments; D010936:Plant Extracts; D012838:Silymarin; C464484:pluronic block copolymer P123; D011060:Poloxalene; C041902:insulin B (20-30)
GSH; MDA; Nkx6.1; Pdx-1; SOD; STZ; diabetes; insulin; silymarin; silymarin-loaded pluronic nanoparticles